Jim Cramer is Recommending These 5 Stocks in June

4. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 53   

Eli Lilly and Company (NYSE:LLY) develops and markets human pharmaceuticals. The journalist investor gave the stock a Buy recommendation during the Discussed Stock segment of his show on June 7. Cramer identified the company as a “recession” stock and one which investors who are fleeing to safety are likely to pick up in light of interest rate hikes by the Fed. Cramer has previously advised his viewers to buy the stock for the long-term potential it offers with regards to the drug pipeline. 

On June 6, Mizuho analyst Vamil Divan maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) stock with a price target of $356, noting that the firm was the top investment pick in the large-cap drug business. 

Among the hedge funds being tracked by Insider Monkey, Florida-based investment firm GQG Partners is a leading shareholder in Eli Lilly and Company (NYSE:LLY), with 1.6 million shares worth more than $485 million.  

In its Q4 2021 investor letter, Saturna Capital highlighted a few stocks and Eli Lilly and Company (NYSE:LLY) was one of them. Here is what the fund said:

“Industrials and pharmaceutical companies were among the Amana Income Fund’s strongest performers in the fourth quarter. Industrials and pharmaceutical companies were among the Amana Income Fund’s strongest performers in the fourth quarter. Drug maker Eli Lilly and Company (NYSE:LLY is represented in the 10 Largest Contributors.”